

# MOVING FORWARD TO 90-90-90

## ANALYSIS OF A COHORT OF RECENTLY-DIAGNOSED PATIENTS IN A TERTIARY HOSPITAL IN BUENOS AIRES, ARGENTINA.

D'Aurizio M<sup>1</sup>, Jaume M<sup>1</sup>, Barletta J<sup>1</sup>, Stover S<sup>1</sup>, Villegas I<sup>1</sup>, Rey M<sup>1</sup>, Vigo G<sup>1</sup>, Blugerman G<sup>1</sup>, Cando O<sup>2</sup>, Rolón M<sup>1</sup>, Perez H<sup>1</sup>.

<sup>1</sup> Infectious Diseases Division, Hospital Juan A. Fernández, CABA, Argentina.

<sup>2</sup> Virology, Hospital Juan A. Fernández, CABA, Argentina.



**1<sup>st</sup> Andean Pacific Workshop on  
HIV & HEPATITIS**

30 June - 1 July 2017 • Santiago, Chile

# DISCLOSURE




I have no conflict of interest to declare.

# BACKGROUND




- Although access to diagnosis and treatment has markedly improved since the beginning of HIV pandemic, patients are still diagnosed in late-stage disease.
- WHO/UNAIDS 90-90-90 strategy intends to reduce transmission and deaths due to HIV/AIDS.



diagnosed



on treatment




virally suppressed

# BACKGROUND



- In Argentina, 32% of men and 23% of women are still diagnosed in late-stage disease.




# MATERIAL & METHODS




- Retrospective cohort.
- Patients with HIV diagnoses during 2016.
- Assessments:
  - demographics
  - clinical, immunologic and virologic data at diagnosis
  - patients who had initiated HAART by March-2017



# RESULTS



# RESULTS: DEMOGRAPHICS



**32 years**  
Median age.  
IQR: 25-41



# RESULTS: DEMOGRAPHICS



## COUNTRY OF BIRTH








# RESULTS: STAGE AT DX


**295** cél/μl  
Median CD4 count  
RIC: 118-461

**476.286**  
copies/ml  
Communitary VL

### Clinical Stage




### CD4 count



- Acute Retroviral Syndrome
- AIDS-related disease
- AIDS-defining disease
- Asymptomatic

- CD4 < 200
- CD4 ≥ 200

# RESULTS: STAGE AT DX




**MALE**                      **FEMALE**                      **TRANS**

■ Acute Retroviral Syndrome      ■ AIDS-related disease  
■ AIDS-defining disease            ■ Asymptomatic

## Clinical stage stratified by gender

# RESULTS: STAGE AT DX

p=0,03



<25Y                      25-40Y                      >40Y


■ Acute Retroviral Syndrome      ■ AIDS-related disease  
■ AIDS-defining disease            ■ Asymptomatic

## Clinical stage stratified by age

# RESULTS: STAGE AT DX



p=0,1




CD4 count stratified by gender

# RESULTS: STAGE AT DX




$p < 0,01$



CD4 count stratified by age

# RESULTS: OI



**43 pts 23%**  
Had an opportunistic infection at diagnosis.



# RESULTS: FOLLOW UP

**204 patients**

With VL data available.



# RESULTS: HAART

**144 patients**



Were followed at our center.

**94,4%**

Started HAART by  
March-2017

**42 days**

Median from Dx to  
HAART initiation  
IQR:20-79 days.





# CONCLUSIONS

---

---



- Late-stage diagnosis is still frequent.
- Vulnerable groups have greater burden of disease.
- Loss to follow-up is a concern, even when specific retention-programs are implemented.
- Starting HAART in 90% of diagnosed patients seems to be an achievable goal.
- Further follow up of this cohort will be presented to define the proportion of patients who achieve virologic suppression.